Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Signaling and Regulation

EWS-Fli1 Up-Regulates Expression of the Aurora A and Aurora B Kinases

Kazuhiko Wakahara, Takatoshi Ohno, Masashi Kimura, Takahiro Masuda, Satoshi Nozawa, Taikoh Dohjima, Takatoshi Yamamoto, Akihito Nagano, Gou Kawai, Aya Matsuhashi, Mitsuru Saitoh, Iori Takigami, Yukio Okano and Katsuji Shimizu
Kazuhiko Wakahara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takatoshi Ohno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masashi Kimura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takahiro Masuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Nozawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taikoh Dohjima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takatoshi Yamamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akihito Nagano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gou Kawai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aya Matsuhashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitsuru Saitoh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iori Takigami
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukio Okano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katsuji Shimizu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1541-7786.MCR-08-0054 Published December 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

EWS-Fli1, a fusion gene resulting from the chromosomal translocation t(11;22, q24;q12), encodes a transcriptional activator, promotes cellular transformation, and is often found in Ewing sarcoma and primitive neuroectodermal tumor. The Aurora A and Aurora B kinases belong to a highly conserved family of serine/threonine protein kinases, are tightly regulated during the cell cycle, and are overexpressed in many carcinomas. Because the relationship between the Aurora A and/or Aurora B genes and the EWS-Fli1 fusion gene is unknown, we investigated the regulatory mechanism(s) by which Aurora kinases are controlled. Knockdown of EWS-Fli1 by small interfering RNA reduced mRNA levels not only of EWS-Fli1 but also of Aurora A and Aurora B. Luciferase assay using Aurora A and Aurora B promoters showed up-regulated activities compared with those of an empty vector. Experiments with deletion and point mutants showed positive regulatory Ets-binding sites located −84 and −71 bp upstream of the transcription initiation sites in Aurora A and Aurora B, respectively. Moreover, chromatin immunoprecipitation assay revealed that EWS-Fli1 gene products interact with both the Aurora A and Aurora B promoters. These results strongly suggest that the mitotic kinases Aurora A and Aurora B are regulated by EWS-Fli1 fusion protein in Ewing sarcoma cells. (Mol Cancer Res 2008;6(12):1937–45)

Keywords:
  • EWS-Fli1
  • Aurora
  • Ets-binding element

Introduction

Ewing family tumor is a rare type of bone and soft tissue tumor, accounting for ∼2% of cases of childhood cancer (1-4). Cytogenetic and molecular analyses of Ewing family tumor indicate that the 5′-region of the EWS gene (from band 22q12) is fused to the Fli1 gene (from band 11q24) or the Erg gene (from band 21q22), both of which are members of the Ets family of transcription factors. Less frequently, chromosomal translocations are observed between the same region of the EWS gene and various other Ets genes, such as ETV-1, E1AF, or FEV (5, 6). Previously, we showed that EWS protein is an RNA-binding protein and that EWS binds preferentially to polyguanylic acid and polyuridylic acid (1). The RNA-binding activity of the EWS protein is located in the RGG box, which lies in the COOH-terminal region, whereas the NH2-terminal region of the EWS protein regulates RNA-binding activity (1). Ets family transcription factors, characterized by an evolutionarily conserved Ets domain, play important roles in cell development, cell differentiation, cell proliferation, apoptosis, and tissue remodeling (7, 8). The Ets domain of about 85 amino acid residues mediates binding to purine-rich DNA sequences with a central GGAA core consensus sequence (7, 8). Functional characterization of EWS-Fli1 and EWS-Erg chimeric proteins suggests that they act as sequence-specific transcriptional activators and are able to transform cells (1, 9-11). Antagonism of EWS fusion gene expression in tumors results in reduced tumorigenicity and clonogenicity, suggesting that their chimeric products must be expressed above a threshold level to maintain oncogenicity (1, 11). EWS-Fli1 binds to DNA by using the same consensus sequence as Fli1, and the NH2-terminal region of EWS is capable of activating the promoters of target genes (6, 9). Several target genes of EWS-Fli1 have been identified, such as c-fos, manic fringe, NKX2.2, PTPL1, NR0B1, platelet-derived growth factor C, Id2, thrombospondins, telomerase, and transforming growth factor-β receptor (12-23).

Aurora A and B, a highly conserved family of serine/threonine protein kinases, are tightly regulated during the cell cycle and are overexpressed in many carcinomas, such as hepatocellular, ovarian, esophageal, bladder, breast, prostate, pancreas, and lung cancers (24-34). Human Aurora A, B, and C have been implicated in different aspects of mitosis. The Aurora A gene maps to chromosomal region 20q13.2, which is frequently amplified in a diverse array of human cancers. Aurora A protein localizes to the centrosome and is required for centrosome maturation and spindle formation (35-37). The Aurora B gene maps to human chromosomal region 17q13.1 (38). The Aurora B gene product shows an intracellular localization pattern typical of chromosomal passenger proteins, which relocate from the centromere to the equatorial region along the midzone after onset of anaphase and are required for chromosome segregation and cytokinesis (39-42). The Aurora C gene product is abundant in the testis and has a function in male meiosis (43). Levels of mammalian Aurora A and B proteins are regulated by transcription and protein degradation during the cell cycle (40, 44, 45). Both Aurora A and B are overexpressed at the mRNA and protein levels in a variety of human cancers. Overexpression of both Aurora A and B is linked to centrosome amplification, leading to chromosomal instability and aneuploidy, and consequently malignant transformation (35, 40, 43, 45). Relationships between expression of the Aurora A and B gene products and prognosis or malignant stage have been reported for many types of malignant tumor (13, 24, 25, 46-48). In addition, overexpression of Aurora A can transform rodent fibroblasts, as studied by growth in soft agar and in nude mice (49). Moreover, genetic variants of Aurora A are significantly associated with increased risk of cancer occurrence (49). These results suggest that Aurora kinases have an important role in various cancers.

In the present study, we first examined the relationship between the Aurora A or Aurora B genes and the EWS-Fli1 fusion gene. Knockdown of EWS-Fli1 by small interfering RNA (siRNA) led to reductions in mRNA and protein levels of EWS-Fli1, Aurora A, and Aurora B. In addition, the EWS-Fli1 fusion gene up-regulated the transcription of Aurora A and Aurora B. Both the Aurora A and Aurora B promoters contain positive regulatory elements required for EWS-Fli1 binding. The Aurora A and Aurora B promoters both interact with EWS-Fli1 gene products, as detected by chromatin immunoprecipitation assay. These results strongly suggest that EWS-Fli1 up-regulates Aurora A and Aurora B transcription in Ewing sarcoma.

Results

Knockdown of EWS-Fli1 in TC135 Cells Leads to Reduction of Aurora A and B mRNA or Protein Levels

To understand the relationships between EWS-Fli1 and the mitotic kinases Aurora A and B, their expression levels were investigated in EWS-Fli1 knockdown cells. We confirmed the findings of our previous studies indicating that the expression of EWS-Fli1 protein or mRNA is reduced by EWS-Fli1 siRNA (50, 51). In this study, we also examined by reverse transcription-PCR the levels of Aurora A and B mRNA in TC135 cells treated with EWS-Fli1 siRNA. There were reductions in expression of all of these mRNAs in cells transfected with EWS-Fli1 siRNA compared with those transfected with irrelevant control RNA (Fig. 1A ). Protein levels of Aurora A, Aurora B, and EWS-Fli1 were reduced by transfection with EWS-Fli1 siRNA (Fig. 1B). Knockdown of EWS-Fli1 caused marked decreases in both protein and mRNA of Aurora A and Aurora B, indicating its regulatory role with respect to these kinase genes.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Knockdown of EWS-Fli1 leads to decreases in mRNA and protein of Aurora A and Aurora B. The Ewing sarcoma cell line TC135, containing the type I EWS-Fli1 fusion gene, was transfected with siRNA for EWS-Fli1 or irrelevant (IR) RNA by using Lipofectamine 2000. After 48 h, total RNA was isolated and subjected to reverse transcription-PCR (RT-PCR) to amplify the cDNA fragments of EWS-Fli1, Aurora A, and Aurora B (A) or protein levels of EWS-Fli1, Aurora A, and Aurora B that were measured by Western blotting (B).

EWS-Fli1 Gene Product Is a Positive Regulator of Aurora A and/or Aurora B Transcription

We examined whether EWS-Fli1 activates the transcription of Aurora A and Aurora B by using the plasmids pGL3A-1486 and pGL3B-1879, respectively. Both promoter regions contain Ets-binding sites (Fig. 2A ). Endogenous EWS-Fli1 protein was detected in TC135 and A673, but not in HT1080, cells (Fig. 2B). These constructs were cotransfected with the phRL-SV40 reference vector into TC135 and A673 cells, which carry EWS-Fli1, or into HT1080 cells, which do not carry EWS-Fli1. For Aurora A, the luciferase activities of pGL3A-1486 were significantly higher than those of empty vector (pGL3) in all three cell lines, as shown in Fig. 2C (P < 0.05). However, there was no significant difference in the luciferase activities of pGL3A-1486 in TC135 and A673 cells. On the other hand, the activity of pGL3A-1486 in HT1080 cells was ∼40% of that in TC135 cells (P < 0.05). For Aurora B, the luciferase activities of pGL3B-1879 were significantly higher than those of pGL3 in all three cell types. Additionally, the luciferase activity in HT1080 cells was only 20% of that in TC135 and A673 cells, as shown in Fig. 2D (P < 0.05). These results indicate that the promoter activities of both Aurora A and Aurora B are significantly up-regulated in TC135 cells, which carry EWS-Fli1, compared with HT1080 cells, which do not, suggesting that Aurora A and Aurora B are genes lying downstream of the transcriptional regulator EWS-Fli1.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Aurora A and Aurora B promoter activities in TC135, A673, and HT1080 cells. A. Schematic representation of human Aurora A (pGL3A-1486) and Aurora B (pGL3B-1879) promoters containing putative Ets-binding elements (GGAA). Numerals indicate nucleotide number from the transcription initiation site. B. The protein levels of EWS-Fli1 and actin in TC135, A673, and HT1080 cells were measured by Western blotting. Luciferase activities of TC135, A673, or HT1080 cells were measured 48 h after transfection of the promoter constructs pGL3A-1486 (C) or pGL3B-1879 (D) or the control vector pGL3. Results are expressed as the ratio of luciferase activities in each cell extract relative to that in TC135 cells transfected with pGL3A-1486 or pGL3B-1879. All assays were repeated individually at least thrice.

Identification of a Positive Regulatory Region for EWS-Fli1 in the Aurora A and Aurora B Promoters

To confirm the expression levels of EWS-Fli1 in HT1080 cells transfected with EWS-Fli1 expression vector, Western blotting was done (Fig. 3A ). EWS-Fli1 protein was overexpressed in TC135 cells after mock transfection and in HT1080 cells transfected with pEWS-Fli1, but not in HT1080 transfected with empty vector or after mock transfection. On the other hand, Fli1 protein was detected in all HT1080 cell lines examined, but not in TC135 cells. These results show that TC135 has endogenous EWS-Fli1, but not Fli1, whereas HT1080 has endogenous Fli1, but not EWS-Fli1. They also show that transfection of pEWS-Fli1 effectively causes overexpression of EWS-Fli1 protein in HT1080 cells. A series of deletion mutants of the Aurora A and Aurora B promoter regions was generated from pGL3A-1486 and pGL3B-1879 to identify the regions regulated by EWS-Fli1 (Fig. 3B and C). These reporter plasmids were cotransfected with 2 μg of pEWS-Fli1 or empty vector and phRL-SV40 as a reference vector into HT1080 cells. The luciferase activity of pGL3A-1486 in cells cotransfected with pEWS-Fli1 was significantly higher than that in cells cotransfected with empty vector (P < 0.05). Deletion of the sequence from −1486 to −124 in Aurora A did not significantly affect luciferase activity compared with full-length pGL3A-1486. Approximately 50% reduction in activity resulted from deleting the sequence −124 to −75. The reduction induced by deletion of −124 to −75 was greater than that induced by deletion of −75 to +17 (Fig. 3B). These results suggest the presence of an important regulatory sequence between −124 and +17 of the Aurora A promoter. Deletion of the sequence from −1879 to −74 in Aurora B did not affect luciferase activity. Approximately 50% reduction in relative activity was caused by deletion between −74 and +34 (P < 0.05), and a further decrease was caused by deletion between +34 and +171 (P < 0.05). A marginal effect was observed after deletion between +171 and +280 (P = 0.878; Fig. 3C). These results indicate that the regulatory regions for EWS-Fli1 are located in the sequences from −124 to +17 of the Aurora A promoter and from −74 to +171 of the Aurora B promoter.

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Promoter activities of deletion mutants of Aurora A and Aurora B with or without EWS-Fli1. A. Western blotting analysis of EWS-Fli1 and Fli1 expression was done using lysates of TC135 and HT1080 cells with mock transfection and HT1080 cells transfected with pEWS-Fli1 or empty vector. B and C. A series of promoter constructs for Aurora A (B) or Aurora B (C) was cotransfected with phRL-SV40 and pEWS-Fli1 (2 μg) or empty vector (2 μg) into HT1080 cells. Left, schematic representation of the series of deleted promoter regions, containing putative Ets-binding elements, in Aurora A (B) and Aurora B (C). Right, luciferase activities measured with the various deleted promoter constructs indicated on the left. Results are expressed as the ratio of luciferase activities in each cell extract relative to that in cells transfected with pGL3A-1486 (B) or pGL3B-1879 (C). All assays were repeated individually at least thrice.

Effect of Ets Consensus Sequence Mutations in the Aurora A and Aurora B Promoters

Because several groups have reported that the binding site for EWS-Fli1 is the Ets-binding consensus element (GGAA), we examined the effects of point mutations in the Ets-binding element to determine the precise locations of the positive regulatory regions. The experiments above indicated that positive regulatory regions are located from −124 to +17 and from −74 to +280 in pGL3A-1486 and pGL3B-1879, respectively. A computer search revealed one and three Ets-binding sites in the Aurora A and Aurora B promoter regions, respectively. Thus, we generated one promoter mutant (pGL3A-1486-Mut) in pGL3A-1486 for Aurora A, and three mutants (pGL3B-1879-Mut 1, pGL3B-1879-Mut 2, and pGL3B-1879-Mut 3) in pGL3B-1879 for Aurora B, which were then subjected to luciferase assay (Fig. 4 ). The luciferase activity of pGL3A-1486-Mut was markedly decreased to 28% of that of the wild-type promoter (P < 0.05; Fig. 4A). In the Aurora B promoter, we found three Ets-binding sites at positions −71 to −68, +165 to +168, and +265 to +268. The luciferase activity of pGL3B-1879-Mut 1 was significantly reduced to 52% of that of the wild-type promoter (P < 0.05; Fig. 4B). However, the other promoter mutants (pGL3B-1879-Mut 2 and pGL3B-1879-Mut 3) did not show any decrease in luciferase activity compared with the wild-type (P = 0.302 and 0.599, respectively; Fig. 4B). These results confirm that the Aurora A and Aurora B promoters have specific positive regulatory regions at −84 to −81 and −71 to −68, respectively, which are responsible for activation by EWS-Fli1. The results suggest that these Ets-binding sites have an important role in recruiting complexes containing EWS-Fli1 to the Aurora A and Aurora B promoters.

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Promoter activities of mutated Aurora A and Aurora B promoters. Wild-type or mutated promoters of Aurora A (A) or Aurora B (B) were cotransfected with phRL-SV40 and 2 μg of pEWS-Fli1 into HT1080 cells. Left, schematic representation of the various mutants of the Aurora promoters. Wild-type and mutated Aurora A promoter constructs were designated pGL3A-1486 and pGL3A-1486-Mut, respectively. Wild-type and mutated Aurora B promoter constructs were designated pGL3B-1879 and pGL3B-1879-Mut 1, pGL3B-1879-Mut 2, and pGL3B-1879-Mut 3, respectively. The empty vector was pGL3. The mutated Ets sequences and the nucleotide numbers are shown. Right, luciferase activity of the wild-type and several mutated promoters assessed 48 h after transfection. Results are expressed as the ratio of luciferase activities in each cell extract relative to that in cells transfected with the wild-type pGL3A-1486 (A) or pGL3B-1879 (B). All assays were repeated individually at least thrice. Asterisks indicate statistically significant differences by unpaired two-tailed Student's t test.

EWS-Fli1 Gene Products Bind Directly to the Aurora A and Aurora B Promoter Regions

We did chromatin immunoprecipitation assays to investigate whether EWS-Fli1 gene products interact with the Aurora A and Aurora B promoter regions. The TC135 cell line, which expresses the EWS-Fli1 fusion protein, was immunoprecipitated with anti-Fli1 antibody or nonspecific IgG, and the promoter regions of Aurora A and Aurora B were detected by PCR. Bands of the corresponding size were detected from DNA immunoprecipitated with anti-Fli1, but not from DNA immunoprecipitated with control IgG, by using the A-1 or B-1 primer sets (Fig. 5C and G ). On the other hand, DNA fragments were never amplified from DNA immunoprecipitated with anti-Fli1 or control IgG when the A-2 or B-2 primer sets were used (Fig. 5A and E). These results suggest that the 5′-flanking region of Aurora A and Aurora B interacts with EWS-Fli1 in the TC135 cell line. Next, HT1080 cells were cotransfected with wild-type or mutant Aurora promoter constructs in combination with a Flag-tagged EWS-Fli1 expression vector (pFlag/EWS-Fli1). The promoters pGL3A-1486-Mut or pGL3B-1879-Mut 1 were used as mutated promoter constructs. At 48 hours after transfection, each potential component of the EWS-Fli1 complex was precipitated with anti-Flag antibody or nonspecific IgG, and the promoter regions of Aurora A and Aurora B were detected by PCR. When the A-1 primer set was used for PCR, DNA fragments of the Aurora A 5′-flanking region with the expected size were detected in all input samples (Fig. 5D, top). However, no band was detected with nonspecific IgG (Fig. 5D, middle). The complex precipitated with anti-Flag antibody exhibited a band corresponding to the Aurora A promoter only when cells were cotransfected with wild-type pGL3A-1486 and pFlag/EWS-Fli1, but not with the mutant promoter or the empty vector pFlag (Fig. 5D, bottom). On the other hand, when the A-2 primer set was used for PCR, the band was never detected except for the input sample (Fig. 5B). For Aurora B, the DNA fragment was amplified with the B-1 primer set only in the complex from the combination of wild-type pGL3B-1879 and pFlag/EWS-Fli1 (Fig. 5H), a result similar to that obtained with wild-type pGL3A-1486 (Aurora A). These results confirm that complexes containing EWS-Fli1 bind to the Aurora A and Aurora B promoters in vivo and that the binding sites of the EWS-Fli1 gene product in the Aurora A and Aurora B promoters are located at −84 to −81 and −71 to −68, respectively.

FIGURE 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 5.

Detection of EWS-Fli1 binding to the Aurora A and Aurora B promoters by chromatin immunoprecipitation. A, C, E, and G. Each potential component of the EWS-Fli1 complex was precipitated with anti-Fli1 antibody from TC135 cells bearing the EWS-Fli1 fusion protein. As a negative control, the same amount of anti-mouse IgG was used for each sample. Immunoprecipitated DNA was analyzed by PCR with primers specific for the 5′ flanking regions of Aurora A [A-2 (−1643; −1489), A-1 (−177; −17)] and Aurora B [B-2 (−1882; −1735), B-1 (−87; +26)]. As an input, the lysate before immunoprecipitation was subjected to PCR with the same primers. HT1080 cells were cotransfected with combinations of reporter plasmids having Aurora A promoters (wild-type or mutated pGL3A-1486; B and D) or Aurora B promoters (wild-type or mutated pGL3B-1879; F and H) and regulator-encoding plasmids, pFlag/EWS-Fli1 (+) or empty vector (−). Bottom, after 48 h, each potential component of the EWS-Fli1 complex was precipitated with anti-Flag antibody. Middle, as a negative control, the same amount of anti-mouse IgG was used for each sample. Immunoprecipitated DNA was analyzed by PCR with primers specific for the 5′ flanking regions of Aurora A or Aurora B, which are A-1 (D) and A-2 (B) or B-1 (H) and B-2 (F), respectively. Top, as an input for each assay, the lysate before immunoprecipitation was subjected to PCR with the same primers.

Discussion

Our present results indicate that knockdown of EWS-Fli1 by siRNA results in reductions in mRNA and protein levels of EWS-Fli1, Aurora A, and Aurora B. In addition, the EWS-Fli1 fusion gene product interacts with the Aurora A and Aurora B promoters and up-regulates the transcription of these genes.

Several groups have studied Aurora promoter activity by using deleted or point-mutated promoters (26, 36, 39, 40, 45). Transcription of Aurora A is positively regulated by E4TF1, a ubiquitously expressed member of the Ets protein family, and the binding site of E4TF1 is located between −85 and −79 upstream, a region that contains the consensus Ets-binding element GGAA (45). TRAP/MED1 has been reported to bind to E4TF1/GABP and to regulate Aurora A promoter activity via an Ets-binding element (44). The promoter activity of Aurora A is associated with Ets2, which belongs to the Ets family of transcription factors, and the regulatory element of Aurora A is the same site as the E4TF1 site (45). However, the Ets family transcriptional factor Ets1 does not bind to the DNA sequence to which E4TF1 binds. In addition, the amount of Aurora A protein is not decreased by siRNA transfection of the Ets family transcription factor Elk1 (28). These results suggest that only some members of the Ets family of transcription factors bind to the promoter region of Aurora A and up-regulate its transcription. In this study, we showed that EWS-Fli1 binds to the same promoter element and up-regulates its transcription. Conversely, the functional relationships between Ets family transcription factors and the Aurora B promoter have not been studied. Here, we identified the EWS-Fli1–binding site in the Aurora B promoter region and showed that the element can up-regulate Aurora B transcription. This is the first report of a relationship between the Ets family transcription factor EWS-Fli1 and Aurora B expression.

In Ewing family tumors, the EWS-Ets fusion product acts as an oncogene and promotes abnormal cellular proliferation (52, 53). EWS-Fli1 up-regulates c-myc, Id2, hTERT, PTPL1, and NR0B1 and down-regulates p27, p57, p21, transforming growth factor-β receptor, and NKX2.2, suggesting that the amounts of many cell cycle regulators are controlled by the EWS-Fli1 fusion protein. Complexes containing EWS-Fli1 have been shown to interact directly with the Ets-binding site (GGAA) of many promoters and to regulate their activity (12-16, 19, 20, 23 53-56), suggesting that the interaction of EWS-Fli1 with the Aurora A and Aurora B promoters may be direct. However, some investigators have reported a new aspect of the tumorigenic mechanism of EWS-Ets in that the DNA-binding domain is not essential for its transforming activity and some gene promoters are activated by EWS-Ets regardless of the lack of direct binding to DNA (18, 55). Nevertheless, our results strongly suggest that the Aurora A and Aurora B genes are the direct targets of the oncogenic EWS-Fli1 fusion protein via Ets-binding elements in their promoters.

Aurora A and Aurora B are important mitotic regulators, and elevated expression of Aurora A and Aurora B has been reported in various human cancers (24-34). In Ewing sarcoma, Aurora A and Aurora B are up-regulated directly by the EWS-Fli1 fusion gene product. The present investigations indicate that Aurora kinases are potential targets for the treatment of Ewing sarcoma.

Materials and Methods

Cell Culture

TC135 and A673 are Ewing sarcoma cell lines carrying EWS-Fli1. TC135 was provided by Dr. T.J. Triche (University of Southern California, Los Angeles, CA) and A673 was purchased from the American Type Culture Collection. HT1080, a fibroblastoma cell line lacking EWS-Fli1, was purchased from the American Type Culture Collection. TC135 and HT1080 cells were maintained in RPMI 1640 (Invitrogen) containing 10% fetal bovine serum, 100 units/mL penicillin G, and 100 μg/mL streptomycin at 37°C under 5% CO2 (49, 50). A673 cells were maintained in DMEM supplemented with 2 mmol/L l-glutamine and 10% fetal bovine serum at 37°C under 10% CO2 (57).

siRNA and Reverse Transcription-PCR and Western Blotting

The sequences of the EWS-Fli1 siRNA (5′-AGCAGAACCCTTCCTTATGAC-3′) and irrelevant siRNA (5′-AGTCGACGTCAGCTGAAGGC-3′) were as previously described (50, 51). The former has been reported to decrease both the protein and mRNA levels of EWS-Fli1 (50, 51). The siRNAs were transfected into TC135 cells with Lipofectamine 2000, and total RNA was isolated from the cells 48 h after transfection by using ISOGEN (Nippon Gene). Reverse transcription-PCR was done in 20 μL of first-strand buffer containing 0.2 μg of total RNA and 100 ng of oligo(dT) primer with 0.2 μL of PowerScript (Clontech) for 90 min at 42°C followed by heat inactivation for 5 min at 99°C. The primer sets used were as follows: a 153-bp Aurora A cDNA fragment (5′-TGATGATATCGCCGCGCTCGTCGT-3′ and 5′-CACAGCCTGGATAGCAACGTACAT-3′), a 412-bp β-actin cDNA fragment (5′-TGATGATATCGCCGCCGCGCTCGTCGT-3′ and 5′-CACAGCCTGGATAGCAACGTACAT-3′), and a 347-bp Aurora B cDNA fragment (5′-AGAACTCCTACCCCTGGCCCTAC-3′ and 5′-ATGCTCCACGCCCTCCTTCTCTA-3′). PCR was carried out using KOD Plus (TOYOBO) for 32 cycles at 98°C (10 s), 56°C (30 s), and 68°C (30 s) for Aurora A and Aurora B and at 98°C (10 s), 59°C (30 s), and 68°C (30 s) for β-actin (40). For EWS-Fli1, primers (5′-GTGATACAGCTGGCGGCGTTGGCG-3′ and 5′-GCTGCCCGTAGCTGCTGCTCTGTT-3′) were used to generate a 332 bp cDNA product with 35 cycles at 98°C (10 s), 65°C (30 s), and 68°C (30 s; ref. 51).

Cell harvesting and Western blotting were done as described (50). The EWS/Fli1 fusion protein (68 kDa) and Fli1 (51 kDa) protein were detected by Western blotting analysis using an anti-Fli1 antibody (Santa Cruz Biotechnology). Aurora A and Aurora B proteins were detected with anti-Aurora A (46 kDa; ref. 37) and anti-Aurora B (41 kDa) antibodies (Santa Cruz Biotechnology), respectively.

Plasmid Construction for Aurora A, Aurora B, and EWS-Fli1

The EWS-Fli1 expression vector was constructed as described previously (3). We subcloned the coding region of EWS-Fli1 into pCMV-FLAG (Sigma) to produce pFlag/EWS-Fli1.

To obtain the Aurora A reporter plasmid (pGL3A-1486), the genomic DNA fragment containing −1486 to +354 of the 5′-flanking sequence was amplified by PCR with PAC clone RP5-1167H4 (Children's Hospital Oakland Research Institute) with the primer set 5′-AAAGATCTCACATGAGAGATTAGAGGCTG-3′ and 5′-GGGGGATCCCTCTAGCTGTAAGTAAC-3′ and subcloned into the BamHI site of the pGL3 vector (Promega). The plasmids pGL3A-415 and pGL3A+17, which are deletion mutants of pGL3A-1486, were constructed by using appropriate restriction enzymes. To obtain pGL3A-124 and pGL3A-75, the DNA fragments corresponding to −124 to +354 and to −75 to +354 were amplified by PCR with the primer sets 5′-GGGGGATCCTGGGACTGCCACAGGTCTGG-3′ and 5′-GGGGGATCCCTCTAGCTGTAAGTAAC-3′, and 5′-GGGGGATCCCACCACTTCCGGGTTCTTAG-3′ and 5′-GGGGGATCCCTCTAGCTGTAAGTAAC-3′, respectively. Digested PCR products were subcloned into the BamHI site of pGL3 (45).

For Aurora B, the promoter region containing −1879 to +392 of the human Aurora B gene was subcloned into pGL3 (pGL3B-1879) and its deleted promoters were constructed as previously reported (39). Reporter plasmids with mutant Ets-binding sites were generated by PCR-targeted mutagenesis with a QuikChange kit (Stratagene) in accordance with the manufacturer's instructions (40). In pGL3A-1486 (Aurora A), the primer corresponding to the site from −84 to −81 was 5′-GGCCGTTGGCTCCACCACGCGTGGGTTCTTAGGGAGCAAG-3′. In pGL3B-1879 (Aurora B), the primers used for the sites located from −71 to −68 (pGL3B-1879-Mut 1), +165 to +168 (pGL3B-1879-Mut 2), and +265 to +268 (pGL3B-1879-Mut 3) were 5′-CAGGACATCGAGCCAATGCATGCTAGGCTGGGCGACGAG-3′, 5′-CGCGCACGCCGCAGGGCTACGTGGAGGTAGGGACGATAGC-3′, and 5′-ACCAGCTCGGGCTAGCGCGCGTGGCTCGATCGGTCCAACC-3′, respectively. The original Ets sequences (GGAA or TTCC) are mutated as underlined.

Transfection and Luciferase Assay

Reporter genes were transfected into TC135 or HT1080 cells together with phRL-SV40 (Promega) by using FuGene 6 (Roche; refs. 18, 40) and luciferase activity was measured with a luminometer (VERITAS, Promega). Firefly luciferase activities, derived from pGL3 or pGL3A-1486 or pGL3B-1879, were normalized by comparison with Renilla luciferase activities from phRL-SV40 (40, 45).

Chromatin Immunoprecipitation

Chromatin immunoprecipitation was carried out using a chromatin immunoprecipitation assay kit (Upstate Biotechnology) in accordance with the manufacturer's protocol (18-20, 28, 44). TC135 cells or transfected HT1080 cells were fixed with 1% formaldehyde solution for 10 min at 37°C. Complexes containing Flag/EWS-Fli1 were immunoprecipitated with anti-Flag (Sigma), anti-Fli1 (Santa Cruz Biotechnology), or nonspecific normal rabbit IgG (Santa Cruz Biotechnology).

Primer sequences used to generate Aurora A genomic DNA fragments were as follows: region A-1 (−177; −17), 5′-AGGGGCTGTTGCTTCACCGATAA-3′ and 5′-TGACAACAAACCCGACGCCTTGA-3′; region A-2 (−1643; −1489), 5′-AGGGGCTGTTGCTTCACCGATAA-3′ and 5′-TGACAACAAACCCGACGCCTTGA-3′. Primer sequences used to generate Aurora B genomic DNA fragments were as follows: region B-1 (−87; +26), 5′-GGACATCGAGCCAATGGGAACTA-3′ and 5′-AAACAACTGAATCTGCCACGCCG-3′; region B-2 (−1882; −1735), 5′-TATGCATGTAGAGGCTCAACAAT-3′ and 5′-TCTGGAAGTGAGGGAAGCAT-3′. PCR was carried out using KOD-Fx (TOYOBO) for 20 cycles of 98°C (10 s), 57°C (30 s), and 68°C (30 s) for region A-1 and 98°C (10 s), 59°C (30 s), and 68°C (30 s) for region B-1. As negative controls, Aurora A and Aurora B genomic DNA fragment PCR was carried out using KOD-Fx for 25 cycles of 98°C (10 s), 60°C (30 s), and 68°C (30 s) for regions A-2 and B-2.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. T.J. Triche for providing the Ewing sarcoma cells, S Isaji for assistance, and our colleagues at the Department of Orthopaedic Surgery, Gifu University Graduate School of Medicine, for encouragement.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted August 18, 2008.
    • Received January 29, 2008.
    • Revision received August 1, 2008.
  • American Association for Cancer Research

References

  1. ↵
    Ohno T, Ouchida M, Lee L, Gatalica Z, Rao VN, Reddy ES. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 1994;9:3087–97.
    OpenUrlPubMed
  2. Rao VN, Ohno T, Prasad DD, Bhattacharya G, Reddy ES. Analysis of the DNA-binding and transcriptional activation functions of human Fli-1 protein. Oncogene 1993;8:2167–73.
    OpenUrlPubMed
  3. ↵
    Ohno T, Ouchida M, Lee L, Gatalica Z, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res 1993;53:5859–63.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Reddy ES, Rao VN. erg, an ets-related gene, codes for sequence-specific transcriptional activators. Oncogene 1991;6:2285–89.
    OpenUrlPubMed
  5. ↵
    Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001;20:5747–54.
    OpenUrlCrossRefPubMed
  6. ↵
    Arvand A, Welford SM, Teitell MA, Denny CT. The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1. Cancer Res 2001;61:5311–7.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Oikawa T. ETS transcription factors: possible targets for cancer therapy. Cancer Sci 2004;95:626–33.
    OpenUrlCrossRefPubMed
  8. ↵
    Oikawa, T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003;303:11–34.
    OpenUrlCrossRefPubMed
  9. ↵
    Yi H, Fujimura Y, Ouchida M, Prasad DD, Rao VN, Reddy ES. Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene 1997;14:1259–68.
    OpenUrlCrossRefPubMed
  10. Sorensen PH, Shimada H, Liu XF, Lim JF, Thomas G, Triche TJ. Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene. Cancer Res 1995;55:1385–92.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995;11:1049–54.
    OpenUrlPubMed
  12. ↵
    Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS ONE 2008;3:e1965.
    OpenUrl
  13. ↵
    Potikyan G, Savene RO, Gaulden JM, et al. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Res 2007;67:6675–84.
    OpenUrlAbstract/FREE Full Text
  14. Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006;9:405–16.
    OpenUrlCrossRefPubMed
  15. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 2006;4:851–9.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's sarcoma tumorigenesis. Oncogene 2005;24:2715–22.
    OpenUrlCrossRefPubMed
  17. Uren A, Merchant MS, Sun CJ, et al. β-Platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 2003;22:2334–42.
    OpenUrlCrossRefPubMed
  18. ↵
    Takahashi A, Higashino F, Aoyagi M, et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 2003;63:8338–44.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Fukuma M, Okita H, Hata J, Umezawa A. Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 2003;22:1–9.
    OpenUrlCrossRefPubMed
  20. ↵
    Deneen B, Hamidi H, Denny CT. Functional analysis of the EWS/ETS target gene uridine phosphorylase. Cancer Res 2003;63:4268–74.
    OpenUrlAbstract/FREE Full Text
  21. Dohjima T, Ohno T, Banno Y, et al. Preferential down-regulation of phospholipase C-β in Ewing's sarcoma cells transfected with antisense EWS-Fli-1. Br J Cancer 2000;82:16–9.
    OpenUrlCrossRefPubMed
  22. May WA, Arvand A, Thompson AD, et al. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 1997;17:495–7.
    OpenUrlCrossRefPubMed
  23. ↵
    Hahm KB, Cho K, Lee C, et al. Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999;23:222–7.
    OpenUrlCrossRefPubMed
  24. ↵
    Tanaka E, Hashimoto Y, Ito T, et al. The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin Cancer Res 2007;13:1331–40.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Lassmann S, Shen Y, Jutting U, et al. Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res 2007;13:4083–91.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Lopez-Rios F, Chuai S, Flores R, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006;66:2970–9.
    OpenUrlAbstract/FREE Full Text
  27. Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 2006;66:4996–5002.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 2006;25:4831–9.
    OpenUrlCrossRefPubMed
  29. Yamamoto Y, Matsuyama H, Furuya T, et al. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer. Clin Cancer Res 2004;10:6449–55.
    OpenUrlAbstract/FREE Full Text
  30. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004;10:2065–71.
    OpenUrlAbstract/FREE Full Text
  31. Mayer F, Stoop H, Sen S, et al. Aneuploidy of human testicular germ cell tumors is associated with amplification of centrosomes. Oncogene 2003;22:3859–66.
    OpenUrlCrossRefPubMed
  32. Sen S, Zhou H, Zhang RD, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320–9.
    OpenUrlAbstract/FREE Full Text
  33. Takahashi T, Futamura M, Yoshimi N, et al. Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn J Cancer Res 2000;91:1007–14.
    OpenUrlCrossRef
  34. ↵
    Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999;59:2041–4.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Zhou H, Kuang J, Sen S, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189–93.
    OpenUrlCrossRefPubMed
  36. ↵
    Kimura M, Matsuda Y, Okano Y, et al. Assignment of STK6 to human chromosome 20q13.2→q13.3 and a pseudogene STK6P to 1q41→q42. Cytogenet Cell Genet 1997;79:201–3.
    OpenUrlCrossRefPubMed
  37. ↵
    Kimura M, Kotani S, Okano Y, et al. Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1. J Biol Chem 1997;272:13766–71.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Kimura M, Matsuda Y, Yoshioka T, Sumi N, Okano Y. Identification and characterization of STK12/Aik2: a human gene related to aurora of Drosophila and yeast IPL1. Cytogenet Cell Genet 1998;82:147–52.
    OpenUrlCrossRefPubMed
  39. ↵
    Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006;12:6869–75.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Kimura M, Uchida C, Takano Y, Kitagawa M, Okano Y. Cell cycle-dependent regulation of the human aurora B promoter. Biochem Biophys Res Commun 2004;316:930–6.
    OpenUrlCrossRefPubMed
  41. Ota T, Suto S, Katayama H, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002;62:5168–77.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Tatsuka M, Katayama H, Ota T, et al. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 1998;58:4811–6.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Kimura M, Matsuda Y, Yoshioka T, Okano, Y. Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem 1999;274:7334–40.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Udayakumar TS, Belakavadi M, Choi KH, Pandey PK, Fondell JD. Regulation of Aurora-A kinase gene expression via GABP recruitment of TRAP220/MED1. J Biol Chem 2006;281:14691–9.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Tanaka M, Ueda A, Kanamori H, et al. Cell-cycle-dependent regulation of human aurora A transcription is mediated by periodic repression of E4TF1. J Biol Chem 2002;277:10719–26.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Landen CN, Jr., Lin YG, Immaneni A, et al. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 2007;13:4098–104.
    OpenUrlAbstract/FREE Full Text
  47. Hayama S, Daigo Y, Yamabuki T, et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res 2007;67:4113–22.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Chen J, Li D, Wei C, et al. Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res 2007;13:3100–4.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052–65.
    OpenUrlAbstract
  50. ↵
    Nozawa S, Ohno T, Banno Y, Dohjima T, Wakahara K, Fan DG, Shimizu K. Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells. J Biol Chem 2005;280:27544–51.
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Dohjima T, Lee NS, Li H, Ohno T, Rossi JJ. Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther 2003;7:811–6.
    OpenUrlCrossRefPubMed
  52. ↵
    Thompson AD, Teitell M, Arvand A, Denny CT. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. Oncogene 1999;18:5506–13.
    OpenUrlCrossRefPubMed
  53. ↵
    Spahn L, Siligan C, Bachmaier R, Schmid JA, Aryee DN, Kovar H. Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein. Oncogene 2003;22:6819–29.
    OpenUrlCrossRefPubMed
  54. Matsunobu T, Tanaka K, Iwamoto Y, et al. The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors. Cancer Res 2006;66:803–11.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    Dauphinot L, De Oliveira C, Melot T, et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 2001;20:3258–65.
    OpenUrlCrossRefPubMed
  56. ↵
    Welford SM, Hebert SP, Deneen B, Arvand A, Denny CT. DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem 2001;276:41977–84.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    Coleman N, Roberts I. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet 2004;148:86.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Molecular Cancer Research: 6 (12)
December 2008
Volume 6, Issue 12
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
EWS-Fli1 Up-Regulates Expression of the Aurora A and Aurora B Kinases
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
EWS-Fli1 Up-Regulates Expression of the Aurora A and Aurora B Kinases
Kazuhiko Wakahara, Takatoshi Ohno, Masashi Kimura, Takahiro Masuda, Satoshi Nozawa, Taikoh Dohjima, Takatoshi Yamamoto, Akihito Nagano, Gou Kawai, Aya Matsuhashi, Mitsuru Saitoh, Iori Takigami, Yukio Okano and Katsuji Shimizu
Mol Cancer Res December 1 2008 (6) (12) 1937-1945; DOI: 10.1158/1541-7786.MCR-08-0054

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
EWS-Fli1 Up-Regulates Expression of the Aurora A and Aurora B Kinases
Kazuhiko Wakahara, Takatoshi Ohno, Masashi Kimura, Takahiro Masuda, Satoshi Nozawa, Taikoh Dohjima, Takatoshi Yamamoto, Akihito Nagano, Gou Kawai, Aya Matsuhashi, Mitsuru Saitoh, Iori Takigami, Yukio Okano and Katsuji Shimizu
Mol Cancer Res December 1 2008 (6) (12) 1937-1945; DOI: 10.1158/1541-7786.MCR-08-0054
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Wnt3 Promotes EMT and Acquired Resistance to Trastuzumab
  • Analysis of RAF-MEK-ERK Signaling in Pancreas Cancer
  • Patched Functions in Multidrug Transport
Show more Signaling and Regulation
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement